Here's the link:-
https://www.proactiveinvestors.co.uk/companies/news/1043762/angle-shares-up-as-nhs-move-reveals-potential-of-liquid-biopsy-systems-1043762.html
"It emerged on Friday that lung cancer sufferers will be offered a pioneering blood test that will potentially fast-track them to targeted therapies that can be less harsh than traditional treatments.". "A further 10,000 patients with suspected lung cancer will be offered it across 80 NHS Trusts in England over the next year.".
As I understand it this is Illumina's what you might call general DNA blood test. This looks for dead cancer cell fragments hoping that the persons cancer is of a type that exhibits certain biosigns that can be targeted by modern drugs. However Angle has demonstrated (RNS's dated 4th and 20th Jan) that unless the circulating tumour cells are also tested these signs MIGHT BE MISSED!!!. Angle found targetable biosigns in some circulating tumour cells THAT WERE NOT FOUND IN THE GENERAL BOOD ANALYSIS!!!! If they do not also test the CTC's then this vital information might be missed.
The biggest multi billion dollar Companies like Illumina, Thermo Fisher and Roche must be aware of this by now. Angle's Parsortix machine can catch Circulating tumour cells (CCT's) from the same blood sample as the general test referred to above. With Angle's system 99% of the cells are live and undamaged, ideal for testing.
All IMHO.
For lung cancer is ****JUST THE START****. There are massive SAVINGS to be had using this tech because the only other way to obtain cancerous cells to test is to cut them out, normally involving surgery!! The NHS is using Illumina's platform which Angle also uses. "A further 10,000 patients with suspected lung cancer will be offered it across 80 NHS Trusts in England over the next year." The only way to get 100% of the available information is to ALSO ANALYSE THE CIRCULATING TUMOUR CELLS at the same. This is where Angle's parsortix machine can help as it can catch these cells, 99% of which are live and undamaged. If the NHS add this ability which seems to be the ONLY WAY they can check all the anailabe DNA then Angle's sp will be in the stratosphere. Also of course the UK's King and now the Princess of Wales is drawing attention to the fight against cancer.
https://www.bbc.co.uk/news/health-68624334
https://www.bbc.co.uk/news/uk-wales-65377533
All IMHO
The NHS is creating it's own Circulating Tumour Biomarker Network which has tested 2000 and will test another 10,000 who have lung cancer. It's when they then start using liquid biopsies for Breast, Bladder, Colorectal, Kidney, blood, liver, pancreatic, prostrate, thyroid and the other 90 or so types you should really start to worry. LOL! What with the King and the Princess of Wales drawing attention to cancer as well. The Americans will no doubt be investiong more in Co's that are to do with fighting cancer. All in all I think you are going to have a bad day tomorrow with your AGL short position. You know that, don't you as you have been posting over the weekend.............
https://www.england.nhs.uk/blog/nhs-genomic-networks-of-excellence-a-transformative-new-approach-to-healthcare-challenges-in-the-nhs/
Al IMHO.
"The Circulating Tumour Biomarker Network is the truest testament to this. It is being setup to provide to expedite the introduction of ctDNA and ****other liquid biopsy tests**** into NHS cancer care. Liquid biopsy is a genomic blood test that can detect tumours in the body, reducing the need for an invasive biopsy. The test can shorten diagnosis times, with some patients starting the appropriate treatment for cancer much earlier in the pathway compared with a tissue biopsy."
https://www.england.nhs.uk/blog/nhs-genomic-networks-of-excellence-a-transformative-new-approach-to-healthcare-challenges-in-the-nhs/
Things are really starting to move!!!
For lung cancer is ****JUST THE START****. There are massive SAVINGS to be had using this tech because the only other way to obtain cancerous cells to test is to cut them out, normally involving surgery!! The NHS is using Illumina's platform which Angle also uses. "A further 10,000 patients with suspected lung cancer will be offered it across 80 NHS Trusts in England over the next year." The only way to get 100% of the available information is to ALSO ANALYSE THE CIRCULATING TUMOUR CELLS at the same. This is where Angle's parsortix machine can help as it can catch these cells, 99% of which are live and undamaged. If the NHS add this ability which seems to be the ONLY WAY they can check all the anailabe DNA then Angle's sp will be in the stratosphere. Also of course the UK's King and now the Princess of Wales is drawing attention to the fight against cancer.
https://www.bbc.co.uk/news/health-68624334
https://www.bbc.co.uk/news/uk-wales-65377533
All IMHO.
Moab.
Angle have FDA approval for their Parsortix machine to be used to catch breast cancer circulating tumour cells that might be found in a blood sample from a person who has breast cancer. This breast cancer market in itself is huge as we know. This also means the machine is not approved in the USA for catching other types of cancer tumour cells, which seems extremely odd to me but I assume there is some good reason why. I do however find that hard to understand as the Parsortix machine has been used to catch various types of cancer cells, there is loads of documantation to prove this. FDA approval is USA only. It seems to me then at minimum the Parsortix machine can be used in the USA to catch breast cancer cells, analyse them using Illumina, Thermo Fisher, or any other Co's kit, to see if they have actionable DNA. The clinician presumably would take this into consideration when advising what treatment. Actionable DNA can be specifically targeted by some modern drugs as we know.
As far as the rest of the world goes what is the situation? I suppose in most if not all countries the bar to allow your machine to be used will be a lot lower than the USA. Clearly in Wales they are already using Illumina kit to help decision making as this BBC article shows for lung cancer.
https://www.bbc.co.uk/news/health-68624334
https://www.bbc.co.uk/news/uk-wales-65377533
All IMHO.
This is very recent news, Angle RNS was only 4th Jan this year.
So if the likes on Illumina, Thermo Fisher, Roche etc.... want to do a complete check to see if the cancer in question has DNA that it is aleady known can be targeted with modern drugs they will have to ALSO ANALYSE THE circulating tumour cells!!
Simples!!!!
All IMHO.
Present when DNA analysis is done on a persons general blood ONLY. Like the Ilumina test used to guide the treatment in this BBC article using blood only:-
https://www.bbc.co.uk/news/health-68624334
https://www.bbc.co.uk/news/uk-wales-65377533
So a cancer that contains DNA a modern drug might target for treatment ****could be MISSED**** and the treatment NOT USED. The only way to get the "FULL PICTURE", from metastasized cancer is to test the CTC's at the same time as the general blood sample. Angle's Parsortix machine is the best way to collect the CTC's for the analysis because unlike some methods 99% of them are alive and intact.......................
All IMHO.
In the WORLD (195 Countres) are NOT considering adding the analysis of circulating tumour cells to their existing DNA analysis of blood. This simply does NOT compute. Angle Plc have shown that NOT analysing circulating tumour cells as well as the general blood (currently the norm) *******RISKS MISSING******* finding DNA that can be targeted by readily available treatments!
FFS!!!!!!!!!!!!!!
All IMHO.
Need to be analysed. Then you can get the full picture on what to base a treatment decision. Without also analysing the CTC's vital information ***might Be missed*** that is simply not available from the fragments of DNA in general blood. The best system for catching the circulating tumour cells to analyse is Angle Plc's Parsortix system IMHO. Sooner or later this has to happen. Totally obvious. I expect the DNA analysis Co's are looking into this RIGHT NOW.
Emerald Carrots 22/04/2024.
All IMHO.
From the persons general blood sample in this article "Blood test reveals best lung cancer treatment". "The trial, involving the All-Wales Medical Genomics Service in Cardiff, ***Illumina technology*** and the Life Sciences Hub Wales".
Angle and now the whole industry should now be aware (see Angle's RNS's dated 4th and 20th Jan) that if, from the same blood sample, you analyse the Circulating tumour cells (CTC's) as well you can additional important information that may have been MISSED. In some cases the fragments of DNA would ***NOT*** have given the vital information acted upon in this case, ***but the CTC's would***. This is vital information that could have been missed resulting in the treatment mentioned not being used!!!!!! THE INDUSTRY CANNOT IGNORE THIS MUCH LONGER. ILLUMINA WERE TALKING TO ANGLE ABOUT THE RESULTS (SEE RNS DATED 4TH JAN). HOW CAN YOU OFFER A SYSTEM THAT YOU KNOW CAN SOMETIMES MISS VITAL INFORMATION THAT COULD BE GOT FROM ANALYSING THE CTC'S!!!!!!
"She was offered a blood test, also described as a "liquid biopsy" which looks for fragments of DNA which have broken off tumours and are in the bloodstream. This so-called "circulating tumour DNA" revealed that Kat's cancer growth was being driven by a mutation in the ALK gene. Although uncommon, the mutation is often seen in younger patients with non-small cell lung cancer who, like Kat, are non-smokers.
*****It meant the best treatment for her was a targeted drug called brigatinib.*****." So the information that mean't she was prescribed the "brigatinib" came from analysing the fragments of DNA in the generall blood using ***Illumina's system***. This is the system Angle used to analyse general blood plus the CTC's. *****They found that in some cases just analysisng the genaral blood *****would have MISSED***** finding actionable DNA varients lke the ALK gene******. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Https://www.bbc.co.uk/news/health-68624334
https://www.bbc.co.uk/news/uk-wales-65377533
All IMHO.
Hello.
Correction. Spelling errors and "CCT" accidently used instead of CTC (Circulating tumour cell).
Https://www.ft.com/content/d146dc71-3060-4bc7-bb1b-d60c24193e14
Grail offer the Galleri Test that helps screen for cancer. From a search on google for "what does the galleri test do":-
"The Galleri test analyzes cfDNA fragments to detect abnormalities in methylation patterns that could indicate the presence of cancer. Galleri has been trained on the largest known methylation database to identify patterns common to many cancers.". This is a state of the art test, currently available to help find out if a person has cancer.
Once a person has in their blood "circulating tumour cells" (CTC's) obviously they already have cancer and have had for quite some time as CCT's don't come off the original tumour in the early stages (I think until around stage 4?). Angle's Parsortix machine can catch CTC's, 99% of which are LIVE and intact, ideal for testing in the same way the cfDNA fragments are. Angle are suggesting that similar tech is applied to test CTC's which would give valuable additional information about the state of a persons cancer as treatment progresses. So a test before any treatment to establish the base line. Then tests (every few months?) during treatment. The test would be both to monitor the cfDNA fragments generally in the blood AND to test the CTC's. Both tests to obtain all the information available about the treatments effect. The aim being to find out as soon as possible if the treatment is starting to work, or is having zero effect. If zero effect clearly the treatment could be stopped and another one tried. Receiving treatment that IS NOT WORKING is obviously very, very important to know. This is what Angle are suggesting. Makes sense to me.
All IMHO.
Https://www.ft.com/content/d146dc71-3060-4bc7-bb1b-d60c24193e14
Grail offer the Galleri Test that helps screening for cancer. From search on google for "what does the galleri test do":-
"The Galleri test analyzes cfDNA fragments to detect abnormalities in methylation patterns that could indicate the presence of cancer. Galleri has been trained on the largest known methylation database to identify patterns common to many cancers.". This is a state of the art test, currectly available.
Once a person has in their blood "circulating tumour cells" (CTC's) obviously they already have cancer. Angle's machine can catch CCT's, 99% of which are LIVE and intact, ideal for testing in the same way the cfDNA fragments are. Angle are suggesting that similar tech is applied to test CCT's which will give valuable additional information about the state of a persons cancer as treatment progresses. So a test before any treatment to extablish the base line. Then tests (every few months?) during treatment. The test would be both to monitor the cfDNA fragments generally in the blood AND to test the CCT's to obtain all the information available about the treatments effect. The aim being to find out as soon as possible if the treatment is starting to work, or is having zero effect. If zero effect clearly the treatment could be stopped and another one tried. This is what Angle are suggesting. Makes sense to me.
All IMHO.
I suppose even if the flow rate if just a few hondred barrels per day they would not know that until the lower level is tested!
From RNS dated 11th March:-
"Two flow tests are scheduled, one each in the Upper SFS and SMD-B reservoirs, with each frac and flowback operation expected to take approximately ten days.".
"The Company looks forward to providing an update on completion of the Upper SFS flow test.".
Approximately 10 days from11th is today, the 21st.
TwoGood2Die.
"Probably because Illumina have their own solution and no one is buying any Parsortix machines because they are not FDA approved!".
===============================
Lying again I see.
"Illumina have their own solution". No they don't, not as good as Parsortix. Lie Nr. 1.
"no one is buying any Parsortix machines". Lie Nr. 2.
"they are not FDA approved!". They are approved for use with Breast Cancer in the USA as you undoubtedly know. Lie nr. 3. Shows the sort of person you are.
Also they do not have to be approved for cancer research. Lie nr 3a.
Are you capable of posting a single sentence that has any truth in it at all? I suspect not.
Surely no-one on here listens to anything you say considering your track record.
All IMHO.
Bantham.
You say " Newland has a track record of failure.".
Presumably you mean the failure to sell anything like the amount of Parsortix machines originally expected?
Last year, I think that without any assays to go with it (so the client had to do them) or standardised staining kits the expected sales of the machine were totally unrealistic. Now of course Angle have developed some assays and staining kits that they offer to sell with the machine making it more user friendly. Also they offer a service from their lab which uses in house Parsortix machines to catch and analyse circulating tumour cells (blood sample sent in from client) in many, many different ways. Including the molecular analysis that Mr Newland described as "a game changer".
Indeed this side is extremely interesting and, at least at the moment, I too believe the molecular analysis side really could be a "game changer" for Angle. Seems to make sense. Companies like Illumina and Thermo Fisher already sell machines that analyse a standard blood sample for so called "actionable DNA variants". If found these already known DNA varients can give important information to the clinician about the cancer helping treatment decision making. Now as we know Angle have made the breakthrough that using the same process on circulating tumour cells (ctc's) that Parsortix can catch can give important ADDITIONAL information for the clinician. Presumably this is accurate and totally up to date information as the circulating tumour cell will have come from the cancer tumour looking to seed itself somewhere else in the body. As Mr Newland has said these Companies could offer Parsortix to their existing and new clients who may well want this additional information to get all of the available information, the "Full Picture". Obviously Mr Newland could do some sort of deal with one or more of these companies and I don't see why they would not be interested.
All IMHO.
My impression of Mr Newland is he's not one to sell anything on the cheap. Possibly quite the opposite in fact. I have done more reseach on the Parsortix system. It ticks all the boxes. Other products can catch circulating tumour cells but Parsortix is quick, 99% of the cells collected are live, intact and not contaminated by the very system used to catch them. You can't get a better circulating cancer tumour cell to test, period. Angle only need half a dozen contracts on the assay side and things will be a lot different. And that does not include the distinct possibility one or more of the molecular analysis Co's will want some sort of deal, maybe even buy them out. We can be sure of one thing. Newland won't do a deal on the cheap. I just hope he does not ask so much no-one will bite.........
All IMHO.